Survival Rate and Prognosis for Brain Cancer

• Brain cancer survival rates vary considerably by tumor type and grade, and are reported as population averages rather than a prediction for any one patient.
• SEER’s combined category “Brain and Other Nervous System Cancer” — which also includes spinal cord tumors, not brain tumors alone — has an overall 5-year relative survival rate of 32.9% for cases diagnosed 2016–2022, rising to 35.3% among the roughly 77% found only at the original site.
• Higher-grade tumors such as glioblastoma generally carry a more difficult brain cancer life expectancy than slower-growing, typically benign tumors such as most meningiomas, though patient-facing statistics don’t break the overall rate down by specific tumor type.
• Tumor type and grade, location, how much can be surgically removed, and a patient’s general health are among the factors affecting brain cancer prognosis most consistently cited in official patient guidance.
• Ongoing research — including FDA-approved targeted therapies for specific genetic mutations and continuing immunotherapy studies — keeps shaping the brain cancer outlook and survival for newly diagnosed patients.

Overview of Brain Cancer Survival Rates

Understanding brain cancer survival rates is often one of the first things patients and families want to know after a diagnosis. These figures describe the share of people who are still alive for a set period after diagnosis, calculated from large groups of past patients with similar cancers. Because every tumor and every patient’s situation differs, published statistics work best as a general reference point rather than a forecast for one specific person.

General Statistics and Averages

Brain tumors cover a wide range of tumor types and growth patterns, so a single number cannot fully capture the outlook for every diagnosis. According to the National Cancer Institute’s SEER Program, one combined category covers this data: Brain and Other Nervous System Cancer. Its overall 5-year relative survival rate is 32.9% for cases diagnosed from 2016 through 2022, rising to 35.3% among the roughly 77% of cases still confined to the original site at diagnosis. This SEER category is not exclusive to brain tumors — the brain and spinal cord together make up the central nervous system, and tumors that begin in the spinal cord are grouped within this same combined statistic, even though brain tumors account for the large majority of the cases behind it. Because the figure spans many different tumor types and grades, some considerably more favorable and others far more difficult, it works as a broad benchmark rather than a number specific to any one diagnosis.

Understanding 5-Year Survival Rates

In practical terms, a 5-year relative survival figure tries to isolate outcomes tied specifically to the cancer diagnosis itself, setting aside deaths from unrelated causes such as heart disease or an accident. It’s a widely used way to summarize outcomes across large groups, but it’s also a historical measure: the patients behind today’s published rate were diagnosed years earlier, so the figure may not fully reflect the effect of more recent treatment developments. For that reason, these statistics work best as general context for a conversation with a care team, not as a prediction of what will happen to one individual.

Factors Affecting Brain Cancer Prognosis

The outlook for someone diagnosed with a brain tumor depends on a combination of characteristics specific to the tumor and to the person who has it. Per cancer.gov’s patient treatment summary, these factors affecting brain cancer prognosis come down to several things weighed together: how aggressive the tumor looks under a microscope (its grade) and exactly where it sits within the nervous system, whether surgeons can safely take it out and whether any cells are left behind once they try, particular genetic changes found inside the tumor, how healthy the patient is apart from the tumor itself, and whether this is a first diagnosis or a return of the disease.

Tumor Type and Grade

Brain tumors are broadly grouped as primary, meaning they start in the brain, or metastatic, meaning they spread there from cancer elsewhere in the body; per SEER, metastatic brain tumors are more common overall than primary ones. Among primary tumors, MedlinePlus lists gliomas and meningiomas as the most common in adults. Gliomas grow out of the brain’s glial support cells and split into subgroups — astrocytic tumors (ranging from astrocytoma up through glioblastoma), oligodendroglial tumors, and mixed forms. cancer.gov’s patient materials classify glioblastoma as a grade IV astrocytoma that “grows and spreads very quickly,” also known by its older name, glioblastoma multiforme, and often singled out as the single most aggressive primary brain tumor. Meningiomas, by contrast, are usually noncancerous, though some can be cancerous and aggressive depending on size and location. Tumors are also assigned a grade reflecting how quickly they’re likely to grow; grade IV tumors are described as generally unable to be completely removed by surgery, while lower-grade tumors tend to grow more slowly. A tumor’s biologic behavior can also change over time, sometimes becoming a higher grade than it was at diagnosis.

Patient Age and Overall Health

According to SEER, brain and other nervous system cancers are most frequently diagnosed in people aged 65 to 74, with a median age at diagnosis of 61, reflecting that these tumors are, on the whole, more common later in life. NINDS notes that how a glioma is likely to behave hinges partly on how far along it already is, plus individual variables such as the patient’s age and broader medical background. A patient’s general health is also one of the factors cancer.gov’s patient materials list as relevant to prognosis for a primary brain tumor. Given how much these circumstances differ from one person to the next, it’s the treating care team — with full knowledge of a patient’s history and the tumor’s specifics — who can actually translate the general statistics into what they might mean for that individual.

Brain Cancer Life Expectancy by Type

Because “brain cancer” covers dozens of distinct tumor types, brain cancer life expectancy looks different depending on which type is involved — general statistics provide an average, but a tumor’s own type and grade shape the individual picture more directly.

Glioma and Glioblastoma Outlook

Gliomas make up a large share of primary brain tumors in adults, and glioblastoma — the most aggressive of the astrocytic tumor types — is the one most often associated with a challenging glioblastoma outlook. Neither cancer.gov’s patient-facing treatment summary nor SEER’s Cancer Stat Facts publishes a survival percentage specific to glioblastoma or to any other individual brain tumor subtype; instead, prognosis for these tumors is framed in terms of grade, location, extent of surgical removal, molecular changes, and whether the disease is newly diagnosed or recurrent. What is established is the direction of the relationship: higher-grade, more aggressive gliomas such as glioblastoma are consistently associated with a more difficult course than lower-grade gliomas, and ongoing research continues to look for ways to improve outcomes for this group.

Meningioma and Other Tumors

Meningiomas develop from the thin tissue layers that wrap around the brain and spinal cord, and they generally carry a more favorable outlook than high-grade gliomas. Per MedlinePlus, meningiomas — along with the related schwannomas — typically appear between ages 40 and 70; most are noncancerous, though a minority are malignant and can still cause serious complications depending on where they sit and how large they get. As with glioblastoma, neither SEER nor cancer.gov’s patient materials publish a specific survival percentage for meningioma; the more favorable outlook associated with these tumors reflects their typically slow growth and benign behavior rather than a published statistic. Other primary brain tumor types — including ependymomas, craniopharyngiomas, and pituitary tumors — are comparatively rare in adults, and their outlook is likewise described qualitatively rather than through a single number.

Interpreting Brain Cancer Survival Statistics

Population-level brain cancer survival rates offer useful context, but understanding what they do and don’t represent is essential to using them well.

Limitations of Survival Data

SEER frames this limitation plainly: population-derived numbers describe outcomes for large cohorts, not for any single patient, and treatment responses can differ substantially from one person to the next. The rates reported today reflect people diagnosed years in the past — for the current SEER figures, from 2016 through 2022 — so they may not capture the benefit of treatment approaches introduced more recently. They also don’t account for a patient’s specific tumor biology, overall resilience, or quality of life during and after treatment, all of which matter alongside the raw numbers.

Advancements in Treatment

Research into brain and other central nervous system tumors continues to evolve. NINDS reports that several of today’s treatments for these tumors were experimental only a decade ago, and that current studies are exploring biological therapies and immunotherapies — including antibodies, gene therapy, and vaccine-based approaches — intended to help the immune system respond to tumor cells. Some of that progress has already reached patients: the FDA has cleared targeted drugs for tumors with specific genetic changes like BRAF and IDH mutations, and tumor treating fields — a device-based therapy that uses electrical fields to disrupt cancer cell division — is now a standard option specifically for glioblastoma. Starting treatment promptly tends to be linked with better odds of a favorable result, and enrolling in a clinical trial is one way to reach newer approaches as they become available.

Frequently Asked Questions

What is the survival rate for brain cancer?

There’s no single figure that applies to every brain tumor. One SEER tracking category covers this ground: Brain and Other Nervous System Cancer, which also includes spinal cord tumors. Its overall 5-year relative survival rate is 32.9% for cases diagnosed from 2016 through 2022, rising to 35.3% for cases still localized to the original site at diagnosis. This figure spans many different tumor types, grades, and patient ages; more aggressive tumors such as glioblastoma are associated with a more difficult course, while typically benign tumors such as most meningiomas tend to have a considerably more favorable outlook, even though official statistics don’t publish a separate percentage for each subtype.

How do doctors determine the prognosis for a brain tumor?

According to the National Cancer Institute, a primary brain tumor’s outlook rests on several pieces weighed together: how the tumor is graded and classified, precisely where it lies within the brain or spinal cord, whether it can be surgically removed and whether anything remains afterward, specific genetic changes found in the tumor tissue, the patient’s overall condition, and whether the diagnosis is new or a recurrence. For metastatic brain tumors, clinicians instead weigh a different set of clues: how many separate deposits have formed, whereabouts they sit within the nervous system, how the disease has responded to treatment so far, and whether the primary cancer elsewhere in the body remains active. Imaging, biopsy results, and input from a multidisciplinary care team all feed into this assessment.

Are brain cancer survival rates improving?

Long-term data point toward gradual improvement. SEER’s 5-year relative survival trend, tracked for cases diagnosed between 1975 and 2018, shows an upward trajectory over that period, and more recent SEER figures show age-adjusted new-case rates falling by about 1.4% a year over 2014–2023, with death rates declining more modestly, about 0.3% a year over 2015–2024. Continued research into targeted therapies and immunotherapy, along with FDA approvals for treatments aimed at specific genetic mutations, suggests this gradual trend is likely to continue, though progress varies by tumor type and individual results are never guaranteed.

Sources

• National Cancer Institute – Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version
• National Cancer Institute – Cancer Stat Facts: Brain and Other Nervous System Cancer
• MedlinePlus – Brain tumor – primary – adults
• National Institute of Neurological Disorders and Stroke – Brain and Spinal Cord Tumors